Vertex Pharmaceuticals Inc (VRTX)vsVerizon Communications Inc (VZ)
VRTX
Vertex Pharmaceuticals Inc
$429.82
+1.13%
HEALTHCARE · Cap: $107.87B
VZ
Verizon Communications Inc
$47.22
+0.28%
COMMUNICATION SERVICES · Cap: $196.65B
Smart Verdict
WallStSmart Research — data-driven comparison
Verizon Communications Inc generates 1039% more annual revenue ($139.15B vs $12.22B). VRTX leads profitability with a 35.5% profit margin vs 12.5%. VZ appears more attractively valued with a PEG of 0.89. VZ earns a higher WallStSmart Score of 68/100 (B-).
VRTX
Strong Buy66
out of 100
Grade: B-
VZ
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+57.2%
Fair Value
$992.87
Current Price
$429.82
$563.05 discount
Margin of Safety
-4.4%
Fair Value
$45.11
Current Price
$47.22
$2.11 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Earnings expanding 61.4% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 24 in profit
Attractively priced relative to earnings
Large-cap with strong market position
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 25.2%
Generating 3.8B in free cash flow
Areas to Watch
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
2.9% revenue growth
4.3% earnings growth
Weak financial health signals
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.
Bull Case : VZ
The strongest argument for VZ centers on P/E Ratio, Market Cap, PEG Ratio. PEG of 0.89 suggests the stock is reasonably priced for its growth.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Bear Case : VZ
The primary concerns for VZ are Revenue Growth, EPS Growth, Piotroski F-Score.
Key Dynamics to Monitor
VRTX profiles as a mature stock while VZ is a value play — different risk/reward profiles.
VRTX carries more volatility with a beta of 0.30 — expect wider price swings.
VRTX is growing revenue faster at 7.8% — sustainability is the question.
VZ generates stronger free cash flow (3.8B), providing more financial flexibility.
Bottom Line
VZ scores higher overall (68/100 vs 66/100). VRTX offers better value entry with a 57.2% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Verizon Communications Inc
COMMUNICATION SERVICES · TELECOM SERVICES · USA
Verizon Communications Inc. is an American multinational telecommunications conglomerate and a corporate component of the Dow Jones Industrial Average. The company is headquartered at 1095 Avenue of the Americas in Midtown Manhattan, New York City, but is incorporated in Delaware.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?